- The new GS Xceed™ Gene Expression System provides up to a 6 week reduction in cell line construction allowing for faster generation of clonal cell lines and ultimately faster time to the clinic.
- This advanced expression platform will now be available for use globally in all major pharmaceutical and biotechnology markets, including Asia.
- The GS Xceed™ System is the latest generation of Lonza’s industry-leading gene expression platform achieving titers of up to 6 g/L.
Basel, Switzerland, 10 July 2012 - Lonza, a world leader in gene expression and biopharmaceutical development of protein therapeutics, announced today the launch of the new GS Xceed™ Gene Expression System. This is the latest generation of Lonza’s world renowned GS System™, which has already been used to create over 100 high producing cell lines and 13 therapeutic drugs currently on the market. The GS Xceed™ System has been shown to reduce cell line development timelines by up to 6 weeks over the existing CHOK1SV based system and has achieved titers of up to 6 g/L. Both emerging and established companies with protein therapeutics in their pipeline can access this new system by either a Research Evaluation Agreement or a Commercial License. The new system is also available worldwide, allowing multinational companies global access to the system in all pharmaceutical and biotechnology markets.
“We are very pleased to offer our global customers a robust, easy to use, next generation expression system, based on the proven GS technology that has become the industry standard,” said Janet White, Head of Lonza Development Services. “Our new GS Xceed™ Gene Expression System allows our customers to significantly reduce their timelines for the generation of clinical supply material while continuing to achieve titers well above industry standards.”
The key element of the new system is the CHOK1SV GS Knock-out host cell line, which is a derivative of Lonza’s suspension adapted CHOK1SV host cell line in which both alleles of the endogenous glutamine synthetase gene have been “knocked out”. Cell lines are selected in Lonza’s Version 8 (v8) Commercial Platform Process which allows for faster future scale-up into a GMP manufacturing system. Successful cell line construction, selection and development are on the critical path to achieving first in human studies. By shortening the development timeline by up to 6 weeks, customers gain a significant advantage in their product development lifecycle. The complete GS Xceed System™ includes, cGMP banked CHOK1SV GS-KO host cells, GS expression vectors, full protocols, access to Lonza’s latest Commercial Platform Production Process (chemically defined, animal component-free media and feeds system) and access to Lonza’s GS technical team. For more information on the new GS Xceed™ System, please visit us at www.lonza.com/gsxceed.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.
Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
[email protected]